Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
News|Articles|May 30, 2025
Pharmacy Practice in Focus: Oncology
- July 2025
- Volume 7
- Issue 5
ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer
Advertisement
Advertisement
Hormone receptor-positive (HR+) breast cancer (BC) is the most common subtype of all BC diagnoses, accounting for nearly 70% of all cases. Initial treatment for patients with HR+ BC typically includes CDK4/6 inhibitors, which have led to improved outcomes for patients. However, approximately 50% of patients progress after 18 months of initial treatment. These patients have limited options, underscoring the need for more targeted therapeutic approaches.1
Related to this article
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Advertisement
Advertisement